and Human Services (HHS)
NIDDK ADMINISTRATIVE SUPPLEMENTS FOR HUMAN EMBRYONIC CELL LINE RESEARCH RELEASE DATE: December 12, 2002 NOTICE: NOT-DK-03-002Update: July 7, 2009 This Notice is superseded by NIH-OD-09-116 NIH Guidelines
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (http://www.niddk.nih.gov) The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces the availability of administrative supplements to NIDDK grantees to conduct research using human embryonic stem cell (hESC) lines. The purpose of these supplements is to enable NIDDK grantees with little or no prior experience working with hESCs to explore the use of hESC as a model system to further research that is directly related to the aims of the parent grant. The supplemental funds also may be used to foster scientific collaborations between investigators established in the use of hESCs and current NIDDK investigators with little or no experience in their use. Potential applicants are strongly encouraged to contact NIDDK staff to discuss potential supplemental requests at an early stage of the application process. The cell line used must be listed on the NIH Registry of hESC lines (http://escr.nih.gov). NIDDK-funded investigators may request up to $75,000 in direct costs for a period of up to one year. The parent grant must have at least one year of funding remaining at the time of the supplement award. For requests for scientific collaboration support, the one-year, $75,000 cap still applies, and the application must be submitted by an NIDDK grantee. The work proposed must be within the scope of the research recommended by peer review. For example, investigators carrying out animal ES or nonembryonic human adult stem cell work may elect to request funding to extend their investigations to hESC lines. Investigators with current NIDDK grant support in related areas may also apply. However, in all cases careful explanation and justification must be included to document that the proposed work is within the scope of an existing, funded application. Investigators must independently contact the hESC line providers listed on the NIH Registry and make arrangements including any required material transfer agreements (MTA) so the hESC line can be obtained. Applicants must state which hESC line or lines will be used and include a letter from the provider stating that the provider will supply the hESC line. The investigators should also demonstrate either prior experience that may be applied to work with hESC lines or an outline of plans for obtaining expertise to culture hESCs. The hESC line providers, other laboratories with hESC experience, or laboratory training courses on hESC methods are potential means of obtaining this training. Other means for acquiring hESC expertise may be proposed. There will be two receipt dates for administrative supplement applications in 2003: February 18 and July 1. Awards will be made depending on the receipt of a sufficient number of qualified applications and the availability of funds. To apply for an administrative supplement, send an original letter and one copy countersigned by the grantee institution's authorized business official to Drs. Badman, Karp or Sato at the addresses below. The letter (5 page limit) must include: 1) an abstract of the proposed supplemental activity and how it is related to the parent grant; 2) expected overall impact of the requested supplement on ongoing research results; 3) the NIH code for the hESC line(s)and a letter from the provider indicating the provider(s) will supply the cell line(s); 4) a justification of budget request and funding period; and 5) current contact information for the principal investigator, including telephone number and mailing and e-mail addresses. Although these descriptions should be as concise as possible, sufficient detail must be provided to allow the NIDDK to determine if the request qualifies as an administrative supplement. NIDDK will consider supplement requests from all eligible applicants. Requests will be evaluated according to the following criteria: o The proposed research falls within the scope of the parent grant and is a logical extension of the goals and objectives, but not sufficiently different to constitute new research or program expansion. o Evidence of prior ability to work with hESC lines or an outline of plans for obtaining expertise to culture hESCs. o Documentation and justification of the requested budget. Supplement requests will be reviewed by a committee of NIDDK program staff. Award decisions will be based upon the criteria provided above, availability of funds, and NIDDK programmatic priorities and balance. Direct inquiries regarding program issues to: Dr. David G. Badman Division of Kidney, Urologic, and Hematologic Diseases National Institute of Diabetes and Digestive and Kidney Diseases 6707 Democracy Blvd., Rm. 621, MSC 5458 5458, Bethesda, MD 20892-5458 (For FedEx and UPS, use Bethesda, MD 20817) Phone: (301) 594-7717 Fax: 301-480-3510 Email: db70f@nih.gov Dr. Robert W. Karp Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases 6707 Democracy Boulevard, Room 671, MSC 5450 Bethesda, MD 20892-5450 (For FedEx and UPS, use Bethesda, MD 20817) 301-451-8875 Fax: 301-480-8300 Email: karpr@extra.niddk.nih.gov Dr. Sheryl Sato Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases/NIH 6707 Democracy Plaza, Room 6105, MSC 5460 Bethesda, MD 20892-5460 (For FedEx and UPS, use Bethesda, MD 20817) Phone: (301) 594-8811 Fax: (301) 480-3503 Email: satos@extra.nddk.nih.gov Direct inquiries regarding fiscal issues to: Teresa Farris Marquette Senior Grants Management Specialist NIDDK/DEA/GMB Two Democracy Plaza, Room 728, MSC 5452 6707 Democracy Blvd. Bethesda, MD 20892-5452 (For Courier service, use Zip Code 20817) Phone: (301) 594-7682 Fax: (301) 480-3504 Email: FarrisT@extra.niddk.nih.gov
for Human Stem Cell Research
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||